Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

CG Oncology Q3 2026 Results: Net Loss of $56.9M, Loss Widens

CG Oncology reported a net loss of $196.1 million for the first nine months of 2026, driven by a significant increase in research and development expenses to $137.6 million. The company strengthened its balance sheet through a follow-on public offering that raised $391.6 million, ending the period with over $984 million in cash and marketable securities.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1.61.7
Net income-56.9-43.8
EPS (diluted, $ a share)$-0.64$-0.57

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-3.7%
Source

10-Q filed with the SEC, NASDAQ: CGON. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

CG Oncology, Inc.: key numbers

Share price
$84.78Close, Nov 16
Market cap
$7.57B
Shares outstanding
89.32MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from CG Oncology, Inc.

All →
8:16 AM ET 8-K
Clinical Trial Data

CG Oncology Clinical Trial Data

CG Oncology announced positive topline results from its Phase 3 PIVOT-006 registrational trial of cretostimogene in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer (NMIBC). The trial met its primary endpoint, showing a 68% reduction in the risk of recurrence (hazard ratio of 0.32) compared to the control arm, with no Grade 3 or higher treatment-related adverse events reported.

8:31 AM ET 8-K
Financial Results

CG Oncology Financial Results

CG Oncology reported third quarter 2026 financial results, highlighting a cash position of $984.5 million which is expected to fund operations through 2029. The company is approaching several clinical milestones, including anticipated Phase 3 topline data for PIVOT-006 in November 2026 and the completion of its BLA submission for BCG-unresponsive NMIBC in Q4 2026.

Term
Q3 2026

“We are entering an eventful period for CG Oncology as we look forward to sharing PIVOT-006 topline data this month. As a reminder, PIVOT-006 is the first randomized registrational trial in intermediate-risk and high-grade Ta NMIBC. Additionally, we expect to have 12-month data from both CORE-008 Cohort CX and BOND-003 Cohort P in December, which further strengthens the growing body of evidence for cretostimogene across the NMIBC landscape and supports our goal to address the broadest number of patients. We remain confident in cretostimogene’s potential to become a backbone therapy for patients and to create long-term value for shareholders.”

Arthur Kuan, Chairman, President & Chief Executive Officer
4:30 PM ET Form 4
Insider Selling

CG Oncology Director Leonard E. Post Sells $62.1K of Stock

Leonard E. Post, Director, sold 1,000 shares of CG Oncology, Inc. at $61.65 to $62.48 a share (average $62.06) in 2 transactions, worth $62.1K in total on Oct 15, 2026. Shares held after the trade: 0 (-100.0%).

Value
$62.1K
Shares
1,000
Average price
$62.06
Role
Director
Holding change
-100.0%
Trade date
Oct 15, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.